MD Anderson Cancer Center Prostate Cancer SPORE

描述（由申请人提供）：通过本申请，得克萨斯大学MD安德森癌症中心寻求资金更新其前列腺癌孢子。本申请由主要研究者Christopher J. Logothetis博士和Timothy C.博士根据多名主要研究者计划（MPI）提交。MD安德森前列腺癌SPORE为转化研究创建了一个稳定而动态的基础设施，以满足并成功解决减少前列腺癌患者痛苦和死亡率的具体挑战。我们将继续加强开展新颖、创新的临床试验的能力，并相信我们的转化研究团队开展的新研究项目将在临床实践中取得实质性进展和有意义的变化。在目前的提案中，我们将我们的转化研究挑战和目标定义为（1）定量定义前列腺癌风险，以消除低风险前列腺癌的过度治疗，（2）开发新的治疗方法，以克服去势抵抗性前列腺癌（CRPC）对现有疗法的耐药性，以及（3）开发CRPC和治疗难治性疾病的新替代策略。我们将通过鉴定和测试新的预测和预后生物标志物来确定早期前列腺癌患者的治疗需求，开发和测试CRPC的新免疫疗法，开发和测试克服骨分泌介导的骨转移对治疗的抗性的新方法，以及开发和测试导入组合疗法以最大化CRPC的DNA损伤应答靶向疗法。我们将通过4个研究项目（包括一个人口科学研究项目），3个支持核心（行政，生物统计学和生物信息学，生物标本和病理学），一个动态的发展研究计划和一个有效的职业发展计划来实现我们的目标。我们乐观地认为，通过将基础研究成果转化为临床实践，我们的研究工作将有助于降低这种毁灭性疾病的发病率、发病率和死亡率。

DESCRIPTION (provided by applicant): Through this application, The University of Texas MD Anderson Cancer Center seeks funding for renewal of its Prostate Cancer SPORE. This application is submitted under the Multiple Principal Investigator plan (MPI) by Principal Investigators Drs. Christopher J. Logothetis and Timothy C. Thompson, who are recognized internationally for their research in prostate cancer, The MD Anderson Prostate Cancer SPORE has created a stable and dynamic infrastructure for translational research to meet and successfully address specific challenges in reducing suffering and mortality rates for men with prostate cancer. We continue to build on our capacity to conduct novel, innovative clinical trials and believe that new research projects conducted by our translational research team will yield substantial progress and meaningful changes in clinical practice. In the current proposal, we define our translational research challenges and goals as (1) quantitative definition of prostate cancer risk to eliminate overtreatment of low-risk prostate cancer, (2) development of novel therapeutic approaches to overcoming resistance of castration-resistant prostate cancer (CRPC) to available therapies, and (3) development of novel alternative strategies for CRPC and treatment-refractory disease. We will achieve these translational research goals by identifying and testing novel predictive and prognostic biomarkers to determine the need for therapy in patients with early-stage prostate cancer, developing and testing novel immunotherapy for CRPC, developing and testing a novel approach to overcoming osteocrine- mediated resistance of bone metastasis to therapy, and developing and testing lead-in combination therapy to maximize DNA damage response-targeted therapy for CRPC. We will accomplish our goals via 4 research projects (including one population science research project), 3 support cores (Administrative, Biostatistics and Bioinformatics, and Biospecimen and Pathology), a dynamic Developmental Research Program, and an effective Career Enhancement Program. We are optimistic that our research efforts will contribute to reductions in the incidence, morbidity, and mortality of this devastating disease by translating basic research findings into clinical practice.